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Abstract
Background: In addition to its role in cell adhesion and gene expression in the canonical Wingless/integrated Wnt
signaling pathway, β-catenin also regulates genes that underlie the transmission of nerve impulses. Mutations of
CTNNB1 (β-catenin) have recently been described in patients with a wide range of neurodevelopmental disorders
(intellectual disability, microcephaly and other syndromic features). We for the first time associate CTNNB1 mutation
with hyperekplexia identifying it as an additional candidate for consideration in patients with startle syndrome.
Case presentation: We describe an 11 year old male Polish patient with a de novo nonsense mutation in CTNNB1
who in addition to the major features of CTNNB1-related syndrome including intellectual disability and
microcephaly, exhibited hyperekplexia and apraxia of upward gaze. The patient became symptomatic at the age of
20 months exhibiting delayed speech and psychomotor development. Social and emotional development was
normal but mild hyperactivity was noted. Episodic falls when startled by noise or touch were observed from the
age of 8.5 years, progressively increasing but never with loss of consciousness. Targeted gene panel next
generation sequencing (NGS) and patient-parents trio analysis revealed a heterozygous de novo nonsense mutation
in exon 3 of CTNNB1 identifying a novel association of β-catenin with hyperekplexia.
Conclusion: We report for the first time a clear association of mutation in CTNNB1 with an atypical syndromic
heperekplexia expanding the phenotype of CTNNB1-related syndrome. Consequently CTNNB1 should be added to
the growing list of genes to be considered as a cause of startle disease or syndromic hyperekplexia.
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Background
A novel dominant intellectual disability (ID) syndrome
caused by β-catenin gene (CTNNB1) haploinsufficiency
was recently identified [1]. Mutations in CTNNB1 (chr3:
41,194,837-41,260,096) are responsible for a wide
spectrum of neurodevelopmental disorders. The pheno-
types of all 21 patients with CTNNB1 mutations
reported to date in four different studies are broad and
consistently include several major features: ID and
motor delay with different degrees of severity, speech
impairment, behavioral anomalies, spastic paraplegia,
microcephaly and overlapping facial features [1–4]. In
addition, variable clinical findings may involve brain
MRI abnormalities (corpus callosum thinning and en-
larged ventricles) and spinal anomalies (syringomyelia or
tethered cord) [2]. We report a case of an 11-year-old
boy with a de novo nonsense mutation in CTNNB1 who
presented with mild ID, ataxia, spastic paraplegia, mild
microcephaly and dysmorphic features. Notably our pa-
tient exhibited hyperekplexia and apraxia of upward
gaze, features which to date have not been described in
patients with mutations of CTNNB1.
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Table 1 Clinical findings in patients with mutation in the N-terminal of β-catenin. * Previously published patients [2], n.e. not examined,
n.r. not recorded
Our Patient Patient 5* Patient 10* Patient 13*
Gender M F F M
Gestational weeks 39 40 40 39
Apgar scores 10 9/10/10 n.r. 10/10
Birth weight [g] 2900 3450 3300 3160
Birth length [cm] 53 51 50.8 49
Age at last
examination [y]
11 5 7/12 4 5 6/12
Height [cm] 150 108 104.5 112
Weight [kg] 46 15 14.15 17.2
BMI [kg/m2] 20.4 12.9 13.0 13.7
OFC [cm] 51 47.3 46 48.5
Microcephaly + + + +
Croniofacial dysmorphism
broad nasal tip + + + (+)
small alae nasi + + + -
long and/or flat
philtrum
−/+ +/+ +/+ −/+
thin upper lip
vermillion
+ + + +
Developmental and neurological abnormalities
Truncal hypotonia + + + +
Peripheral
hypertonia/spasticity




moderate severe moderate moderate
did not crawl 24 12 25













+ + + +good
Intellectual disability + + + + (no formal test
available)
Regression + speech ? - -
Behavioral
characteristics
temper tantrums/crying, friendly personality, aggression,








Seizures - - - -
EEG during episodes diffused fast background activity normal normal n.e.
Brain MRI arachnoid cyst, enlarged Sylvius sulcus normal basically
normal
normal
Hearing loss - - - -




Internal abnormalities - - - -
Frequent infections - - - + (infancy)
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Case Presentation
The study was approved by an ethics committee of
Poznan University of Medical Sciences, Poland. Parents
provided written informed consent according to the
Declaration of Helsinki for publication of clinical infor-
mation. The index case, a male patient was born at term
as the first child to healthy, young, non-consanguineous
Caucasian parents. Family history was negative for the
presence of neurological disorders. He weighed 2900 g,
with a good Apgar score. After a normal neonatal
period, delayed psychomotor and speech development
was evident (at 20 months of age he was unable to walk
unassisted and was able to speak only a few words). His
social and emotional development was within normal
range but hyperactivity was observed. No focal lesions
were visualized in 1.5 T MRI; notably in cortex, thalami,
midbrain and medulla, except for a 12–13 mm in diam-
eter arachnoid cyst in the posterior fossa and an en-
larged Sylvian fissure. An EEG recording showed mild
slowing of background activity. The parents had noticed
episodic falls since the age 8.5 years. The episodes were
provoked by noise, touch or rapid movement in the
neighbourhood. Sudden loss in muscle tonus of lower
limbs was observed, together with an increase in axial
muscle tonus. It led to a rapid flexion in knees and hips
provoking a fall. The boy has never had any head injury
while falling, due probably to the extension position of
his trunk. Episodes were short, lasting a second or two,
without loss of consciousness. The boy was able to lift
up by himself very quickly directly afterwards and was
able to recall the entire episode. This sequence was
highly repetitive. A progressive increase in the frequency
of falls was noticed. Neurological examination between
episodes indicated a left hemiparesis with positive
Babinski sign and mild dysarthria. EEG during episodes
showed diffused fast background activity, typical for
hyperekplexia. In the interictal EEG no epileptiform dis-
charges were observed. Levetiracetam was introduced
with good clinical response however the drug was with-
drawn because of behavioral disturbances (aggression,
tendency to cry). Brivaricetam was introduced instead
and the effect was similar to Levetiracetam with fewer
side effects. During the last examination at the age of
11 years problems with speech were shown to have in-
creased and coordination problems appeared. In
addition to episodes of hyperekplexia, he presents with
mild ID, ataxia, truncal hypotonia, bilateral spastic para-
plegia, dysarthria and apraxia of upward gaze. He needs
support to walk. Ophthalmic examination showed astig-
matism and hyperopia with a normal fundus of the eye.
Periodical horizontal nystagmus is present but vision
evoked potentials are normal. The boy has height and
weight within normal ranges, he is mildly dysmorphic
(asymmetric face, right frontal hair upsweep, hypotelor-
ism, deep set eyes, strabismus, diastema, small teeth,
short philtrum, thin upper lip vermillion, prominent
columella, broad nasal tip, small alae nasi, hypoplastic
upper crus of the inner helix), has long slender fingers
and toes, mild scoliosis, gynecomastia, inverted nipples
and microcephaly. He is generally a friendly child, rather
anxious, avoiding eye contact, with episodes of frustra-
tion. Verbal aggression, crying and sleep disturbances
have been also observed (Table 1).
The patient was followed by neuropediatrics and based
upon symptoms including ataxia with progressive pyr-
amidal syndrome, combined with supranuclear vertical
gaze palsy, Niemann-Pick type C disease was assumed
initially. However, sequencing of the entire coding and
flanking regions of NPC1 and NPC2 failed to identify
any pathogenic mutations. We further analyzed the
index case using a NGS gene panel (targeted resequen-
cing) that included 758 OMIM genes (including GLRA1,
GLRB and SLCA) associated with neurological disorders
(genomebiology.com/content/supplementary/s13059-
015-0693-2-s4.xls). Genes were amplified and a library
constructed using an AmpliSeq HiFi mix, proprietary
primers and library kit (Thermo Fisher, Carlsband, CA,
USA) followed by sequencing on the Ion Proton plat-
form following the manufacturer’s protocol (Thermo
Fisher, Carlsband, CA, USA). Sequences were mapped to
hg19 and variants were called and annotated using the
ion torrent pipeline (Thermo Fisher, Carlsband, CA,
USA). Sequencing identified 2985 variants relative to
hg19. By excluding previously reported variants (present
in RefSeq, OMIM, Genbank, dbSNP, 1000 genomes, in-
house database) and only focusing on non-synonymous,
splicing, frameshift, indel and nonsense variants we de-
creased the number to 10 heterozygous changes each in
a different gene (Fig. 1A). All changes were validated by
Sanger sequencing of the index case and parents. Nine
Table 1 Clinical findings in patients with mutation in the N-terminal of β-catenin. * Previously published patients [2], n.e. not examined,
n.r. not recorded (Continued)
Miscellaneous ginecomastia, inverted nipples - feeding
difficulties
-




Feet sandal gap, long toes flat feet normal pes equines
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changes were inherited with the only other variant being
confirmed as a heterozygous de novo nonsense mutation
in exon 3 of CTNNB1 (NM_001098209): c.C232T;
p.Q78X (Fig. 1B).
Conclusions
In this study we present an 11 year old boy in which we
detected a de novo nonsense mutation in β-catenin
(CTNNB1). Mutations of CTNNB1 were recently re-
ported to be associated with a rare ID syndrome with
consistent clinical features including significant motor
delay with hypotonia of the trunk, progressive distal
hypertonia/spasticity of the legs, speech impairment, be-
havioral anomalies, frequently microcephaly and over-
lapping dysmorphic facial features [1–4]. Our patient’s
phenotype was consistent with, albeit generally milder
than major signs of this entity. However, the boy also
suffers from hyperekplexia and apraxia of upward gaze.
These features have not been previously described in pa-
tients with a mutation of CTNNB1.
Hyperekplexia, or human startle disease, (OMIM
#149400) is a rare, nonepileptic, paroxysmal neuroge-
netic disorder characterized by hypertonia and exagger-
ated persistent startle reflex to unexpected auditory,
visual, and somatosensorial stimuli [5, 6]. The cluster of
these symptoms is associated with failure of glycinergic
synaptic transmission often resulting from mutations in
genes encoding presynaptic and postsynaptic proteins
[7]. Hyperekplexia results from mutations in GLRA1 and
GLRB encoding the human glycine receptor and also the
glycine transporter SLCA5 [8, 9]. Later, mutations in the
proteins (GPHN and ARHGEF9) that cluster and
localize the inhibitory glycine and GABA receptors were
identified [10, 11]. However, patients with defects in
these synaptic clustering proteins presented a disorder
that had only a degree of phenotypic overlap with hyper-
explexia. The genetic basis of hyperekplexia in a large
proportion of cases remains to be discovered [12]. In
our case the clinical diagnosis of hyperekplexia is based
on the presence of its typical features: falls as a reaction
to sudden stimuli, paroxysmal character, shortness and
repetitiveness of episodes (that differenciate hyperek-
plexia from episodic falls and dyskinesias), no epilepti-
form EEG discharges during episode nor loss of
conciousness (that are observed in atonic seizures), rapid
recovery (that is never seen in cataplexy). However, the
hyperekplexia in our patient lacks some of cardinal fea-
tures of hyperekplexia such as rigidity during first year
of life, general increase of muscle tonus during an epi-
sode and frequent head injuries. Presence of progressive
neurologic impairment is also not typical for hyperek-
plexia. Therefore, we propose a diagnosis of atypical
hyperekplexia for this patient`s neurological condition.
β-catenin (CTNNB1) belongs to the armadillo family
of proteins responsible for regulation of gene expression
in the canonical Wnt signaling pathway, in addition to
their function in cell adhesion [13]. Wnt family secreted
glycoproteins are highly conserved and modulate cell-
cell communication in cellular processes including cen-
tral nervous system development [14]. A central compo-
nent of this pathway, β-catenin binds the TCF/LEF
transcription factors that are involved in regulation of
many genes [15]. In the thalamus, β-catenin regulates
the expression of genes encoding proteins associated
with excitation of neurons. In the mouse, it binds to
Gabra 3 encoding the GABA receptor, and also to genes
Fig. 1 Filtering strategy used for identification of a causative mutation using trio analysis and NGS-gene panel (a). DNA electrophoregram with
the c.C232T; p.Q78X mutation in exon 3 of CTNNB1 (b)
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responsible for voltage and ligand-gated ion channels:
Cacna1g and Kcna6. This indicates a role of β-catenin in
the maintenance of neuronal excitability [13].
During axonal developmental, the specification of the
axon initial segment (AIS), characterized by a high dens-
ity of voltage-gated Na+ and K+ channels, is critical in
initiating and modulating action potentials [16]. These
ion channels are tethered by ankyrinG (intracellular pro-
tein) to the membrane of the AIS and during this
process, β-catenin is progressively accumulated at the
AIS and is an essential component of this neuronal do-
main [17]. Its enrichment plays a role in dendritic mor-
phogenesis, axonal growth and the maturation of AIS
functions, modulating neuronal excitability and voltage-
gated sodium channels [13, 18]. β-catenin knockdown
decreases voltage-gated sodium currents at the AIS. The
sodium current reduction is most likely due to dimin-
ished ankyrinG tethering at the AIS and the loss of AIS
integrity when β-catenin is absent [17]. This molecular
mechanism underlying neuronal action potential gener-
ation explains β-catenin involvement in disorders related
to neuronal development and excitability [17].
Our patient expresses hyperekplexia, a unique symp-
tom that has not been seen among other reported
CTNNB1 patients. Only in one other case (P14) a pro-
nounced startle response on both auditory and visual
stimuli provoking a breath holding spell was noted with-
out a clear diagnosis of hyperekplexia [2]. Our patient
has a de novo mutation in CTNNB1 (c.C232T; p.Q78X)
which is localized in the N-terminal domain of β-
catenin. Three other patients (P5, P10 and P13) de-
scribed by Kuechler’s et al. also had mutations in the N-
terminal helical domain [2]. This region contains a con-
served short linear motif responsible for binding β-
TrCPE3 ubiquitin ligase, but only when it is phosphory-
lated. Degradation of β-catenin is regulated by this N-
terminal segment. When comparing the clinical findings
for all four patients with mutation in the N-terminal of
β-catenin, consistent phenotypic features emerge with
exception of atypical hyperekplexia and impaired upward
gaze unique to our case (Table 1). In some cases with
CTNNB1 haploinsufficiency syndrome, there are patients
with additional features not seen in others [4]. There is
also, perhaps not surprisingly, inconsistency in the
phenotype resulting from heterozygous loss-of-function
mouse and human mutations, with phenotype in
humans being much more severe [3]. This wide
spectrum of clinical features in cases with CTNNB1 mu-
tations may result from compensatory activity of other
protein partners that can assume the role of β-catenin in
its absence [3]. Plakoglobin for instance (also called γ-
catenin) has a very similar structure and ligand binding
capacity to β-catenin [19]. The data presented here pro-
vides new insight into the role of β-catenin in brain
development and its association with neurodevelopmen-
tal disorders including hyperekplexia. CTNNB1 should
be considered a candidate in patients with hyperekplexia
in whom classical genetic mechanisms identified to date
are negative.
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